Cameron Myhrvold, Carver Biosciences co-founder

The virus shred­der: A Prince­ton spin­out ad­vised by a high-pro­file VC launch­es a Cas13 vi­ral de­fense sys­tem

Cameron Myhrvold is one of those young sci­en­tists who’s been earn­ing dou­ble takes for the cut­ting-edge re­search work he’s been do­ing, even be­fore join­ing Prince­ton in 2020. But af­ter get­ting his PhD in sys­tems bi­ol­o­gy at Har­vard sev­en years ago, he even­tu­al­ly turned to Cas13, a CRISPR ef­fec­tor — Cas9 is the fa­mous one used on DNA — that is tar­get­ed at sin­gle-strand­ed RNA in­stead of dou­ble-strand­ed DNA.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters